
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
Highlights from the European Respiratory Society International Congress Meeting, which took place virtually on September 7-9, 2020.






